Related Experiment Video
Updated: Aug 14, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Immunotoxins for central nervous system malignancy
1Biochemistry Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1414, USA.
Abstract:
Current therapy for primary brain tumors, metastatic brain tumors and leptomeningeal carcinomatosus is inadequate. Monoclonal antibodies and certain biological ligands such as transferrin and epidermal growth factor bind selectively to tumors but in and of themselves have little therapeutic activity. Linking these binding moieties to protein toxins yields new molecules, called immunotoxins, that display enormous cell-type specific toxicity in vitro and could be valuable agents for treatment of CNS cancer. This review discusses our development of immunotoxins to treat brain tumors after systemic, intrathecal and intratumoral injection.
Insights
New immunotoxins show promise for treating brain cancers. By linking tumor-targeting molecules to toxins, these agents offer specific cancer cell killing for primary brain tumors, metastatic brain tumors, and leptomeningeal carcinomatosis.
Area of Science:
- Oncology
- Neuroscience
- Biotechnology
Background:
- Current therapies for primary brain tumors, metastatic brain tumors, and leptomeningeal carcinomatosis are insufficient.
- Monoclonal antibodies and biological ligands show tumor selectivity but lack therapeutic efficacy.
- Immunotoxins, combining binding moieties with protein toxins, offer targeted cancer cell toxicity.
Purpose of the Study:
- To review the development of novel immunotoxins for treating central nervous system (CNS) cancers.
- To explore the potential of immunotoxins in managing challenging brain tumor conditions.
Main Methods:
- Development of novel immunotoxin constructs by linking tumor-specific binding agents (e.g., monoclonal antibodies, transferrin, epidermal growth factor) to potent protein toxins.
- Evaluation of immunotoxin efficacy and specificity in vitro and in preclinical models of CNS cancers.
- Assessment of different administration routes, including systemic, intrathecal, and intratumoral injection.
Main Results:
- Immunotoxins demonstrated significant cell-type specific toxicity against cancer cells in vitro.
- The targeted delivery of toxins via immunotoxins offers a potential strategy for CNS cancer treatment.
- Successful development of immunotoxins for potential application in various brain tumor types.
Conclusions:
- Immunotoxins represent a promising therapeutic strategy for primary brain tumors, metastatic brain tumors, and leptomeningeal carcinomatosis.
- Targeted delivery of potent toxins via immunotoxins could overcome limitations of current inadequate therapies for CNS cancers.
- Further development and clinical investigation of immunotoxins are warranted for effective brain cancer treatment.
